Zyversa Therapeutics Inc (ZVSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -24,952 | -9,413 | -98,298 | -14,123 | -8,084 |
| Depreciation Amortization | N/A | 7 | 11,905 | 50 | 328 |
| Income taxes - deferred | -852 | 7 | -9,479 | -745 | N/A |
| Accounts payable and accrued liabilities | 689 | 889 | 2,406 | 4,540 | -312 |
| Other Working Capital | 1,522 | 970 | 2,600 | 5,657 | -1,020 |
| Other Operating Activity | 18,479 | 22 | 82,145 | -268 | 4,012 |
| Operating Cash Flow | $-5,114 | $-7,520 | $-8,721 | $-4,889 | $-5,076 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | N/A | N/A | 5,230 |
| Common Stock Issued | 2,052 | 6,541 | 19,082 | 0 | N/A |
| Common Stock Repurchased | N/A | N/A | -7 | 0 | N/A |
| Other Financing Activity | 1,633 | -628 | -13,118 | 1,865 | 0 |
| Financing Cash Flow | $3,685 | $5,913 | $5,956 | $1,865 | $5,230 |
| Beginning Cash Position | 1,531 | 3,138 | 5,902 | 1,028 | 175 |
| End Cash Position | 102 | 1,531 | 3,138 | 6,602 | 329 |
| Net Cash Flow | $-1,429 | $-1,607 | $-2,765 | $-3,023 | $154 |
| Free Cash Flow | |||||
| Operating Cash Flow | -5,114 | -7,520 | -8,721 | -4,889 | -5,076 |
| Free Cash Flow | -5,114 | -7,520 | -8,721 | -4,889 | -5,076 |